Heron Therapeutics Inc (HRTX) Expected to Post Quarterly Sales of $24.50 Million
Equities analysts forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will post sales of $24.50 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Heron Therapeutics’ earnings. The lowest sales estimate is $22.50 million and the highest is $28.00 million. Heron Therapeutics posted sales of $10.05 million during the same quarter last year, which suggests a positive year-over-year growth rate of 143.8%. The company is expected to announce its next quarterly earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Heron Therapeutics will report full year sales of $73.26 million for the current fiscal year, with estimates ranging from $71.13 million to $77.00 million. For the next fiscal year, analysts expect that the firm will post sales of $177.08 million, with estimates ranging from $147.00 million to $224.80 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The company had revenue of $19.79 million during the quarter, compared to the consensus estimate of $19.84 million. During the same period last year, the firm posted ($0.77) earnings per share. The company’s revenue was up 130.9% compared to the same quarter last year.
Heron Therapeutics stock opened at $27.85 on Friday. Heron Therapeutics has a 12 month low of $15.00 and a 12 month high of $42.90. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 7.63 and a beta of 1.45.
In related news, VP Kimberly Manhard sold 6,000 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $32.07, for a total transaction of $192,420.00. Following the completion of the sale, the vice president now owns 6,000 shares in the company, valued at $192,420. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kevin C. Tang sold 2,695,000 shares of the company’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total value of $96,346,250.00. The disclosure for this sale can be found here. Insiders sold 2,701,494 shares of company stock valued at $96,553,796 in the last 90 days. Company insiders own 16.20% of the company’s stock.
A number of institutional investors have recently bought and sold shares of HRTX. Amalgamated Bank purchased a new stake in Heron Therapeutics during the second quarter valued at $379,000. NewSquare Capital LLC purchased a new stake in Heron Therapeutics during the second quarter valued at $211,000. Pier 88 Investment Partners LLC purchased a new stake in Heron Therapeutics during the second quarter valued at $451,000. Aperio Group LLC increased its position in Heron Therapeutics by 14.4% during the second quarter. Aperio Group LLC now owns 11,261 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 1,416 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Heron Therapeutics by 339.1% during the second quarter. Wells Fargo & Company MN now owns 265,847 shares of the biotechnology company’s stock valued at $10,329,000 after acquiring an additional 205,302 shares during the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also: Average Daily Trade Volume Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.